Bioatla Stock Performance


USD 6.99  0.96  12.08%   

Bioatla holds a performance score of 14 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.7292, which signifies a somewhat significant risk relative to the market. Let's try to break down what Bioatla's beta means in this case. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Bioatla will likely underperform. Although it is essential to pay attention to Bioatla historical returns, it is also good to be reasonable about what you can do with equity current trending patterns. Our philosophy towards foreseeing future potential of any stock is to look not only at its past charts but also at the business as a whole, including all available fundamental and technical indicators. To evaluate if Bioatla expected return of 2.38 will be sustainable into the future, we have found twenty-one different technical indicators, which can help you to check if the expected returns are sustainable. Use Bioatla maximum drawdown, semi variance, and the relationship between the jensen alpha and potential upside to analyze future returns on Bioatla.
Bioatla Performance
14 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Bioatla are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bioatla sustained solid returns over the last few months and may actually be approaching a breakup point. ...more

Bioatla Price Channel

Quick Ratio12.77
Fifty Two Week Low2.0100
Target High Price68.00
Fifty Two Week High43.7300
Target Low Price5.00

Bioatla Relative Risk vs. Return Landscape

If you would invest  230.00  in Bioatla on May 14, 2022 and sell it today you would earn a total of  469.00  from holding Bioatla or generate 203.91% return on investment over 90 days. Bioatla is currently generating 2.3815% in daily expected returns and assumes 12.4506% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Bioatla, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Daily Expected Return (%)  
       Risk (%)  
Given the investment horizon of 90 days Bioatla is expected to generate 9.79 times more return on investment than the market. However, the company is 9.79 times more volatile than its market benchmark. It trades about 0.19 of its potential returns per unit of risk. The DOW is currently generating roughly 0.07 per unit of risk.

Bioatla Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Bioatla's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bioatla, and traders can use it to determine the average amount a Bioatla's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.1913

Good Returns
Average ReturnsBCAB
Small Returns
Negative Returns
Estimated Market Risk
  actual daily
 96 %
of total potential
Expected Return
  actual daily
 45 %
of total potential
Risk-Adjusted Return
  actual daily
 14 %
of total potential
Based on monthly moving average Bioatla is performing at about 14% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bioatla by adding it to a well-diversified portfolio.

About Bioatla Performance

To evaluate Bioatla Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Bioatla generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Bioatla Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Bioatla stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Bioatla's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Return on Average Assets(0.39) (0.42) 
Return on Average Equity(0.47) (0.48) 
Return on Invested Capital 4.20  4.53 
Return on Sales(381.60) (391.64) 
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people.

Things to note about Bioatla

Checking the ongoing alerts about Bioatla for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Bioatla help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Bioatla Alerts

Equity Alerts and Improvement Suggestions

Bioatla is way too risky over 90 days horizon
Bioatla appears to be risky and price may revert if volatility continues
The company reported the previous year's revenue of 250 K. Net Loss for the year was (100.95 M) with loss before overhead, payroll, taxes, and interest of (58.02 M).
Bioatla currently holds about 219.43 M in cash with (72.36 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.86.
Bioatla has a poor financial position based on the latest SEC disclosures
Over 76.0% of the company shares are held by institutions such as insurance companies
Latest headline from With 32.00 percent CAGR, Chimeric Antigen Receptor -T Therapy Treatment Market Size, Application, Industry Trends Forecast to 2028 - Digital Journal
Continue to Trending Equities. Note that the Bioatla information on this page should be used as a complementary analysis to other Bioatla's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Bioatla Stock analysis

When running Bioatla price analysis, check to measure Bioatla's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioatla is operating at the current time. Most of Bioatla's value examination focuses on studying past and present price action to predict the probability of Bioatla's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bioatla's price. Additionally, you may evaluate how the addition of Bioatla to your portfolios can decrease your overall portfolio volatility.
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Is Bioatla's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
298.3 M
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine Bioatla value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.